Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 134 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017

Summary

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 38 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes. The latest report Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.  The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 4, 18, 8 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Hodgkin Lymphoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Papillary Renal Cell Carcinoma, Peritoneal Cancer, Primitive Neuroectodermal Tumor (PNET), Renal Cell Carcinoma, Adrenal Gland Cancer, Advanced Malignancy, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Gastroesophageal (GE) Junction Carcinomas, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Lymphoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Skin Cancer, Soft Tissue Sarcoma, Ureter Cancer, Urethral Cancer and Urinary Tract Cancer. 

Furthermore, this report also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview 10
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development 11
Products under Development by Stage of Development 11
Products under Development by Therapy Area 12
Products under Development by Indication 13
Products under Development by Companies 17
Products under Development by Universities/Institutes 29
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment 31
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development 37
Aduro BioTech Inc 37
Agenus Inc 38
Alligator Bioscience AB 39
Bristol-Myers Squibb Company 40
Cold Genesys Inc 43
Crown Bioscience Inc 43
Five Prime Therapeutics Inc 44
Globavir Biosciences Inc 44
Humorigin Biotechnology Corp 45
Immunocore Ltd 45
Immunwork Inc 46
Innovent Biologics Inc 46
JHL Biotech Inc 47
MacroGenics Inc 48
MedImmune LLC 49
Merck & Co Inc 51
OncoImmune Inc 51
Premier Biomedical Inc 52
Serometrix LLC 52
Sutro Biopharma Inc 53
Tikcro Technologies Ltd 53
Xencor Inc 54
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles 55
10B-10 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
AGEN-1884 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
AGEN-2041 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Antisense Oligonucleotide to Inhibit CTLA4 for Melanoma - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ATOR-1015 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Bispecific Monoclonal Antibodies to Antagonize PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Bispecific Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Bispecific Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
CG-0070 + Immune Checkpoint Modulator - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
CG-0161 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
durvalumab + IMCgp-100 + tremelimumab - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
durvalumab + tremelimumab - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
FPT-155 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
HOR-010 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
IBI-310 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
ipilimumab - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
ipilimumab + nivolumab - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
JMW-3B3 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
KN-044 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
MEDI-0562 + tremelimumab - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
MEDI-3617 + tremelimumab - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
MK-1308 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Monoclonal Antibodies to Antagonize 1 PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Monoclonal Antibodies to Antagonize CTLA-4 for Metastatic Melanoma - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
ONC-392 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Small Molecule to Antagonize CTLA-4 for Oncology - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Small Molecules to Inhibit CTLA4 for Oncology - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
SNCA-21 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
TE-1254 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
tremelimumab - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
XmAb-20717 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products 119
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products 121
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones 122
Featured News & Press Releases 122
Aug 15, 2017: Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 122
Jul 27, 2017: AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer 122
Jul 26, 2017: NICE approval for nivolumab provides new treatment for advanced blood cancer 123
Jul 24, 2017: U.S. Food and Drug Administration Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma 123
Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015 125
Jul 05, 2017: Combo immunotherapy may herald new standard of care for kidney cancer 125
Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 126
Jun 04, 2017: New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO 126
Jun 04, 2017: Combination therapy shown to shrink tumours in many advanced melanoma patients whose cancer has spread to the brain 127
Jun 04, 2017: First Presentation of Efficacy Data from CheckMate-204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases 128
Jun 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study 129
May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 130
May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015 131
Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 131
Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 131
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 133
Disclaimer 134

List of Tables

Number of Products under Development by Stage of Development, H2 2017 11
Number of Products under Development by Therapy Areas, H2 2017 12
Number of Products under Development by Indications, H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16
Number of Products under Development by Companies, H2 2017 17
Number of Products under Development by Companies, H2 2017 (Contd..1) 18
Products under Development by Companies, H2 2017 19
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 27
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 28
Number of Products under Investigation by Universities/Institutes, H2 2017 29
Products under Investigation by Universities/Institutes, H2 2017 30
Number of Products by Stage and Mechanism of Actions, H2 2017 32
Number of Products by Stage and Route of Administration, H2 2017 34
Number of Products by Stage and Molecule Type, H2 2017 36
Pipeline by Aduro BioTech Inc, H2 2017 37
Pipeline by Agenus Inc, H2 2017 38
Pipeline by Alligator Bioscience AB, H2 2017 39
Pipeline by Bristol-Myers Squibb Company, H2 2017 40
Pipeline by Cold Genesys Inc, H2 2017 43
Pipeline by Crown Bioscience Inc, H2 2017 43
Pipeline by Five Prime Therapeutics Inc, H2 2017 44
Pipeline by Globavir Biosciences Inc, H2 2017 44
Pipeline by Humorigin Biotechnology Corp, H2 2017 45
Pipeline by Immunocore Ltd, H2 2017 45
Pipeline by Immunwork Inc, H2 2017 46
Pipeline by Innovent Biologics Inc, H2 2017 46
Pipeline by JHL Biotech Inc, H2 2017 47
Pipeline by MacroGenics Inc, H2 2017 48
Pipeline by MedImmune LLC, H2 2017 49
Pipeline by Merck & Co Inc, H2 2017 51
Pipeline by OncoImmune Inc, H2 2017 51
Pipeline by Premier Biomedical Inc, H2 2017 52
Pipeline by Serometrix LLC, H2 2017 52
Pipeline by Sutro Biopharma Inc, H2 2017 53
Pipeline by Tikcro Technologies Ltd, H2 2017 53
Pipeline by Xencor Inc, H2 2017 54
Dormant Products, H2 2017 119
Dormant Products, H2 2017 (Contd..1), H2 2017 120
Discontinued Products, H2 2017 121